Belite Bio Inc ADR (BLTE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $171.43 (+0.63%), Market cap $5.75B, 52-week low–high $56.81 ~ $190.30.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Bel
Financial statements, price targets, institutional (13F) holdings and related news for Belite Bio Inc ADR are updated in real time on BlackAll Trade.
Belite Bio Inc ADR trades at $171.43 (+0.63%). Real-time quotes and charts are available on BlackAll Trade.
Belite Bio Inc ADR has a market cap of about $5.75B.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead prod